Page last updated: 2024-12-11
pentamorphone
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 5464186 |
| CHEMBL ID | 2107032 |
| SCHEMBL ID | 120834 |
| MeSH ID | M0163428 |
Synonyms (30)
| Synonym |
|---|
| pentamorphone |
| rx-77989 |
| a-4492 , |
| D05416 |
| 68616-83-1 |
| pentamorphone (usan/inn) |
| rx77989 |
| pentamorphona [inn-spanish] |
| mm4487b4mw , |
| 7,8-didehydro-4,5alpha-epoxy-3-hydroxy-17-methyl-14-(pentylamino)morphinan-6-one |
| unii-mm4487b4mw |
| morphinan-6-one, 7,8-didehydro-4,5-epoxy-3-hydroxy-17-methyl-14-(pentylamino)-, (5alpha)- |
| pentamorphona |
| pentamorphonum |
| pentamorphonum [inn-latin] |
| rx 77989 |
| pentamorphone [usan:inn] |
| 14b-n-pentylaminomorphinone |
| CHEMBL2107032 |
| SCHEMBL120834 |
| pentamorphone [inn] |
| morphinan-6-one, 7,8-didehydro-4,5-epoxy-3-hydroxy-17-methyl-14-(pentylamino)-, (5.alpha.)- |
| pentamorphone [usan] |
| pentamorphone [mart.] |
| (4r,4as,7ar,12br)-9-hydroxy-3-methyl-4a-(pentylamino)-2,3,4,4a-tetrahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinolin-7(7ah)-one |
| Q7165029 |
| DTXSID901018235 |
| pentamorphone; rx 77989;a 4492 |
| penomorphone |
| (4r,4as,7ar,12br)-9-hydroxy-3-methyl-4a-(pentylamino)-2,4,7a,13-tetrahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one |
Research Excerpts
Overview
Pentamorphone is a novel, potent opiate with rapid onset and short duration of action that has been reported to produce analgesia with limited depression of ventilation. It appears to be an analgesic with clinically tolerable side effects in the range 0.12 to 0.24 microgram.kg-1.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Pentamorphone is a new, highly potent opioid reported to have minimal cardiovascular effects in humans and a high therapeutic index in animals. " | ( Pharmacodynamics of pentamorphone during coronary artery bypass grafting in humans. Falinski, BA; Hug, CC; Klochany, A; Sebel, PS, 1992) | 2.05 |
| "Pentamorphone is a novel, potent opiate with rapid onset and short duration of action that has been reported to produce analgesia with limited depression of ventilation. " | ( Depression of ventilatory responses to hypoxia and hypercapnia after pentamorphone. Afifi, MS; Camporesi, EM; Cohen, NA; Glass, PS; Shook, JE, 1990) | 1.96 |
| "Pentamorphone appears to be an analgesic with clinically tolerable side effects in the range 0.12 to 0.24 microgram.kg-1 that merits further evaluation under clinical conditions." | ( Evaluation of pentamorphone in humans: a new potent opiate. Camporesi, EM; Glass, PS; Quill, T; Reves, JG; Shafron, D, 1989) | 1.36 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 6 (75.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.19
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.19) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 4 (50.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (50.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||